The Conversation (0)
Arch Biopartners (TSXV:ARCH;OTCQB:ACHFF) today provided an update on the general results from toxicology and pharmacology studies evaluating Metablok, the Company’s lead drug candidate for treating acute kidney injury. As quoted in the press release: In seven day studies involving rodents and another larger animal species, there were no significant drug-related side effects in the toxicology …
Arch Biopartners (TSXV:ARCH;OTCQB:ACHFF) today provided an update on the general results from toxicology and pharmacology studies evaluating Metablok, the Company’s lead drug candidate for treating acute kidney injury.
As quoted in the press release:
In seven day studies involving rodents and another larger animal species, there were no significant drug-related side effects in the toxicology assessments.
These studies provide the primary safety data to support the Phase I human safety trial for Metablok expected to begin in early 2019. This will be followed by a Phase II trial to test Metablok’s efficacy in the prevention of acute kidney injury in cardiac surgery patients.
The pharmacokinetic results from each toxicology study demonstrated that intravenous administration of Metablok resulted in minimal to no side effects after the infusion period. In addition, the bioavailability and pharmacokinetics observed in both species are expected to support future intravenous (I.V.) administration in patients at multiple dose levels once or twice daily for up to seven days.